texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x
Request an Appointment

West Texas Clinical Trials

Texas Oncology cancer centers in West Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the West Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the West Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the West Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the West Texas area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Biliary Cancer

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Bladder Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Breast Cancer

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: Ph3 Inavolisib + Fulvestrant v. Alpelisib+ Fulvestrant in HR+ HER2- PIK3CA mutated mBC View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE PIK3CA MUTATED LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY(WO43919)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Carcinoid

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Abilene

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Cervical Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Colon Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Endometrial Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Esophageal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Fallopian Tube Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Gall Bladder Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Gastric Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Head and Neck Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Hematologic

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Abilene

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Kidney Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Leukemia

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Liver Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Lung Cancer

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Lymphomas

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Melanoma

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Myelodysplastic Syndrome

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Myelomas

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Ovarian Cancer

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Pancreatic Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Peritoneal Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Prostate Cancer

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Rectal Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Renal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Skin Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Testicular Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Thyroid Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Urothelial Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Uterine Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Vulvar Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Texas Oncology-Abilene

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: Ph3 Inavolisib + Fulvestrant v. Alpelisib+ Fulvestrant in HR+ HER2- PIK3CA mutated mBC View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE PIK3CA MUTATED LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY(WO43919)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Abilene

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Abilene

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Abilene

Phase: I

Texas Oncology-El Paso Cancer Treatment Center Gateway

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Texas Oncology-El Paso Cancer Treatment Center Grandview

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I/II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Texas Oncology-Midland Allison Cancer Center

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Texas Oncology-Odessa West Texas Cancer Center

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Texas Oncology-Wichita Falls Cancer Center

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Phase I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Abilene

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I

Phase I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I/II

Phase II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Abilene

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP) View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Phase II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II/III

Phase III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: Ph3 Inavolisib + Fulvestrant v. Alpelisib+ Fulvestrant in HR+ HER2- PIK3CA mutated mBC View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE PIK3CA MUTATED LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY(WO43919)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global P